How Mounjaro leads to weight loss: improving insulin resistance and the effects of medical weight loss

  • Published:
  • Updated:
  • Written by the Hiro Clinic Medical Weight Loss editorial team
  • 55 min read
Medically reviewed by Dr. Hiroko Oka Reviewed byDr. Hiroko OkaCertified Member, Japanese Society of Internal Medicine Editorial policy
How Mounjaro leads to weight loss: improving insulin resistance and the effects of medical weight loss

In managing obesity and type 2 diabetes, weight loss and improved insulin resistance are key treatment goals. In recent years, among GLP-1 receptor agonists, Mounjaro (tirzepatide) has drawn attention because, through a mechanism different from conventional single GLP-1 agonists, it has shown greater weight loss and better blood sugar control. At the same time, when our editorial team looks at social media posts, we see quite a few people saying, “I’m taking Mounjaro, but I’m not losing weight.” In this article, we explain not only how Mounjaro works and its effects, but also possible causes and what to do when you feel you are not losing weight, the mechanism behind improved insulin resistance, clinical data, and how it compares with other GLP-1 agonists.

Key points firstShort on time? Just read this part

  • Even if you feel your weight is barely changing on Mounjaro, before concluding that the medication isn’t working, it is important to check whether there is anything in your lifestyle you can review
  • Mounjaro is not insulin itself
  • Mounjaro brings about weight loss and improved blood sugar through three pathways: acting on the appetite center, promoting insulin secretion, and improving insulin resistance

What you will learn in this article

  • Possible causes when you feel you aren’t losing weight on Mounjaro
  • Lifestyle habits to review and what to do when you don’t feel much effect
  • How Mounjaro works, clinical data, and comparison with other GLP-1 agonists

If you feel you aren’t losing weight on Mounjaro: possible causes and what to do

Even if you feel your weight is barely changing on Mounjaro, before concluding that the medication isn’t working, it is important to check whether there is anything in your lifestyle you can review. Comments such as “I increased to 5 mg but my weight isn’t going down” or “I’m taking the injections but not losing weight” are common on social media.

Main reasons you may feel you aren’t losing weight

If you don’t feel much effect even while using Mounjaro, factors like the following may be involved.

You eat less, but what you eat is high in calories

Even if your appetite drops, if you have a lot of sugary drinks, sweets, fried foods or meals out, your calorie intake may not fall as much as you expect. In fact, we saw social media posts from people who had cut down how much they ate but kept eating certain high-calorie foods, and their weight did not change.

Not enough protein

When you eat less, you tend to get less protein as well. A lack of protein can lead to loss of muscle mass, which tends to lower your basal metabolism. As a result, you burn fewer calories and may find it harder to lose weight.

Lack of sleep and stress

Lack of sleep can disturb the balance of hormones involved in appetite and make you feel hungry more easily. An increase in “mindless eating” due to stress is another reason weight loss may stall.

You have hit a plateau

Even for people whose weight had been dropping steadily, a “plateau,” where weight loss temporarily stops, is not unusual. It is considered one of the body’s natural responses to protect itself from rapid weight loss.

How the medication works varies from person to person

Some people feel the effect wears off as the days pass after an injection. In fact, some people on social media said, “By the second half of the week, it feels like the effect is gone.” Because how long the effect lasts varies from person to person, if this concerns you, do not increase the dose on your own; talk to your doctor.

What to review when you aren’t losing weight

If you feel your weight is barely changing, try reviewing the following points.

  • Keep a food diary and review your calories and nutritional balance
  • Make a point of eating protein at every meal (meat, fish, eggs, soy products, etc.)
  • Drink plenty of fluids
  • Get enough sleep
  • Make light exercise such as walking a habit
  • Don’t increase or stop the dose on your own; talk to your doctor

Key point

Mounjaro is a medication that helps control appetite and supports weight loss, but the medication alone does not make you lose weight. Lifestyle habits such as diet, sleep and exercise also affect the results. Just because your weight is barely changing at 5 mg does not necessarily mean “the medication isn’t working.” Rather than increasing or stopping the dose on your own, it is important to continue treatment while reviewing the causes and consulting your doctor. Because results vary from person to person, our editorial team believes it is essential to be patient and watch how things progress.

If you would like to talk to a doctor about what may be the cause in your case, why not start with a counseling session?

See pricing plans

Is Mounjaro different from insulin injections?

Mounjaro is not insulin itself. Both are injected under the skin, so they are easily confused, but they work differently in the body. Insulin products “supply missing insulin from outside the body,” whereas Mounjaro (tirzepatide) is a medication that stimulates the pancreas when blood sugar is high so that your body releases its own insulin.

This difference shows up in how likely hypoglycemia is and in changes in body weight. Insulin products act regardless of how high blood sugar is, so they can cause hypoglycemia when, for example, you eat little, and they tend to make weight go up rather than down. Mounjaro, on the other hand, promotes insulin secretion only when blood sugar is high (glucose-dependent), so when used alone it is unlikely to cause hypoglycemia, and together with appetite suppression and slower movement of food out of the stomach, it works in the direction of weight loss.

Insulin productsMounjaro (tirzepatide)
What the drug isInsulin itselfA drug that acts on GIP/GLP-1 receptors (not insulin)
How insulin is suppliedSupplied from outside the bodyPromotes secretion only when blood sugar is high
Risk of hypoglycemiaCan occurUnlikely when used alone
Effect on weightTends to increaseTends to decrease
Main purposeBlood sugar controlBlood sugar control and weight loss

However, if you are already on insulin treatment and use Mounjaro together with it, the risk of hypoglycemia increases. If you are being treated for diabetes, do not start Mounjaro or change doses on your own; always consult your regular doctor.

Mounjaro basics

Mounjaro is a dual-action drug that stimulates both GIP and GLP-1, and greater weight loss and blood sugar improvement than with conventional GLP-1-only drugs have been reported. Mounjaro is a dual-action drug that simultaneously stimulates GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Conventional GLP-1 receptor agonists target only the GLP-1 receptor, but because Mounjaro also acts on the GIP receptor, it has the following features.

  • Lower energy intake through appetite suppression
  • Less body fat through improved lipid metabolism
  • Increased insulin secretion and improved blood sugar
  • Improved insulin resistance

Key point

Because of this dual action, greater weight loss than with conventional drugs has been reported.

How Mounjaro works

Mounjaro brings about weight loss and improved blood sugar through three pathways: acting on the appetite center, promoting insulin secretion, and improving insulin resistance. Mounjaro’s action is mainly explained by the following three pathways.

2.1 Effect on the appetite center

Stimulation of GLP-1 receptors sends signals to the brain’s satiety center and suppresses appetite. GIP action also works synergistically, strengthening the suppression of eating behavior. As a result, calorie intake naturally decreases, leading to weight loss.

2.2 Promoting insulin secretion

Mounjaro acts on pancreatic beta cells to promote insulin secretion in line with blood sugar levels. Because its effect is especially marked when blood sugar is high after meals, the risk of hypoglycemia is kept relatively low.

2.3 Improving insulin resistance

GIP action improves insulin sensitivity in peripheral tissues. Glucose uptake into fat tissue and muscle increases, improving blood sugar homeostasis, and gluconeogenesis in the liver is also suppressed. As a result, insulin resistance is reduced, which also helps improve the condition of type 2 diabetes.

Weight loss in clinical trials

In several clinical trials (the SURPASS series), Mounjaro showed greater weight loss than conventional GLP-1 agonists. The representative trials are the SURPASS series.

  • SURPASS-1 trial (patients with type 2 diabetes, monotherapy)
    • Average weight loss: about 9.5 kg at a weekly dose of 15 mg
    • HbA1c improvement: a reduction of about 2.0%
    • Side effects: mainly gastrointestinal symptoms (nausea, diarrhea)
  • SURPASS-2 trial (comparison with semaglutide)
    • Mounjaro 15 mg: average weight loss of about 12.4 kg (about 13.1%)
    • Semaglutide 1 mg: average weight loss of about 6.2 kg (about 6.7%)
    • Weight loss was statistically significantly greater with Mounjaro

Key point

These results indicate that Mounjaro may be expected to have strong weight-loss effects in people both with and without diabetes.

Medical

How insulin resistance is improved

Mounjaro’s dual GIP/GLP-1 action works to improve insulin resistance from three directions: fat tissue, the liver and muscle. Mounjaro’s dual action is directly related to the improvement of insulin resistance.

4.1 Improvement in fat tissue

Mounjaro is effective in reducing visceral fat, and the balance of adipocytokines secreted by fat cells improves. As a result, insulin signaling in the liver and muscle is strengthened, and blood sugar control improves.

4.2 Improved glucose metabolism in the liver

Gluconeogenesis in the liver is suppressed, and the rise in blood sugar after meals is reduced. Because GIP action increases insulin sensitivity in the liver, more efficient glucose metabolism can be expected.

4.3 Increased glucose uptake in muscle

Expression of the glucose transporter (GLUT4) in muscle increases, and glucose use in peripheral tissues improves. Through this action, it both curbs rises in blood sugar and improves insulin resistance.

Mounjaro compared with conventional GLP-1 agonists

Clinical trials have shown that Mounjaro exceeds conventional GLP-1 agonists in both the amount of weight loss and the improvement in HbA1c. Comparing Mounjaro with conventional GLP-1 agonists (e.g., semaglutide, liraglutide), the following points stand out.

ItemMounjaroConventional GLP-1 agonists
ActionDual GIP + GLP-1 actionGLP-1 action only
Weight lossAbout 10–15 kgAbout 6–10 kg
HbA1c improvementAbout 2.0%About 1.5%
Gastrointestinal symptomsModerate, common at the start of treatmentModerate, similar
Dosing frequencyOnce-weekly subcutaneous injectionSubcutaneous injection once weekly to daily

This table shows that Mounjaro has greater effects on weight loss and on improving insulin resistance than conventional drugs.

Side effects and precautions

Mounjaro is generally considered well tolerated, but side effects, mainly gastrointestinal symptoms such as nausea and diarrhea, have been reported, and depending on your medical history, careful judgment is needed before using it. Mounjaro is generally well tolerated, but the following side effects have been reported.

  • Nausea and vomiting
  • Diarrhea and constipation
  • Injection site reactions
  • The risk of hypoglycemia is low when used alone, but caution is needed when combined with sulfonylureas

In addition, careful administration is recommended for patients with a history of pancreatitis or gallbladder disease.

Dosing strategy and tips for continuing treatment

Because Mounjaro is given once weekly and gradually increased from a low dose, it is easier to plan a treatment that you can continue while keeping gastrointestinal symptoms under control. Because Mounjaro is given once weekly, it is easy to keep up with. A gradual dose-escalation method, starting at a low dose and increasing it every 2–4 weeks, is recommended. This approach makes it easier to aim for effective weight loss while limiting gastrointestinal symptoms.

Future research

Because Mounjaro is a relatively new drug, more research is needed on its long-term safety and its effect on preventing cardiovascular events. Mounjaro is still a new drug, and future research topics include the following.

  1. Verifying long-term weight loss in people with obesity who do not have diabetes
  2. Confirming effects on preventing cardiovascular events
  3. Optimizing weight loss through combination therapy
  4. Establishing individualized dosing strategies

Through this research, Mounjaro is expected to become established as a safer and more effective option for treating obesity.

Summary

  • Through its dual GIP and GLP-1 action, Mounjaro shows excellent effects on both weight loss and improving insulin resistance
  • It also contributes to blood sugar control by suppressing appetite and improving glucose metabolism in the liver and muscle
  • Greater weight loss than with conventional GLP-1 agonists has been reported
  • Managing gastrointestinal symptoms and gradual dose escalation are key to continuing treatment
  • Research on long-term safety and on preventing cardiovascular events will be important going forward

Clinical precautions when using Mounjaro

While Mounjaro has strong effects on weight loss and blood sugar, attention to three points is essential: managing gastrointestinal symptoms, the risks of concomitant medications, and long-term safety. While Mounjaro shows strong weight-loss and blood sugar-lowering effects, the following points need attention when using it.

10.1 Managing gastrointestinal symptoms

The most commonly reported side effects are nausea, diarrhea and constipation. These are common early in treatment and can be reduced by increasing the dose gradually. Combining this with a “gradual meal reduction” approach, in which you cut down your meal portions little by little, can further lower the risk of gastrointestinal symptoms.

10.2 Cautions about concomitant medications

When used together with sulfonylureas (SU drugs) or insulin, the risk of hypoglycemia increases, so dose adjustment is needed. Careful monitoring is especially required for older adults and patients with reduced kidney function.

10.3 Safety of long-term use

At present, Mounjaro is a relatively new drug, and continued careful observation is recommended regarding the risks of cardiovascular events and pancreatitis with long-term use. Regular blood tests and clinical evaluations are essential.

An individualized approach to treatment

Because Mounjaro’s effects and side effects vary from person to person, individualized strategies based on body build, concomitant medications and lifestyle determine the success of treatment. The effects of Mounjaro vary from person to person. The degree of weight loss and how side effects appear differ depending on age, sex, underlying conditions and lifestyle, so individualized strategies such as the following are important.

  • Setting the starting dose based on BMI and body fat percentage
  • Assessing risk based on the type of concomitant medications
  • Combining treatment with lifestyle improvements (diet and exercise)
  • Regular evaluation of weight changes and blood sugar control

Combining these individualized strategies makes it easier to achieve both treatment effectiveness and safety.

Outlook

Going forward, as long-term safety is verified and individually optimized dosing schemes are established, Mounjaro’s position as an option for treating obesity and diabetes is expected to become clearer. Mounjaro is attracting attention as a drug that makes possible a level of weight loss and improvement in insulin resistance that was difficult to achieve with GLP-1-only drugs. Future challenges include the following.

  • Verifying long-term weight loss in people with obesity who do not have diabetes
  • Long-term evaluation of effects on reducing cardiovascular events
  • Establishing optimal dosing schemes for high-risk patients
  • Examining the effects of combining it with other lifestyle improvement programs

As this research progresses, Mounjaro is likely to be positioned as one of the central drugs in obesity treatment and diabetes management.

Summary

Mounjaro is a drug that shows strong weight-loss effects through dual GIP/GLP-1 action, but when your weight is barely changing, it is important not to jump to conclusions about the medication and instead to prioritize reviewing your lifestyle and consulting a doctor. Here is a recap of what we have covered, including what to consider when you feel you aren’t losing weight.

  • Through its dual GIP and GLP-1 action, Mounjaro shows strong effects on both weight loss and improving insulin resistance.
  • By suppressing appetite and improving glucose metabolism in the liver and muscle, it also improves blood sugar control at the same time.
  • Clinical trials have confirmed greater weight loss than with conventional GLP-1 agonists.
  • Side effects (nausea, diarrhea) are more likely early in treatment, so management with gradual dose escalation is recommended.
  • Combining an individualized treatment strategy with lifestyle improvements may help you get the most out of treatment.
  • Even if you feel your weight is barely changing, that alone does not necessarily mean “the medication isn’t working”; there may be room to review your diet, protein intake, sleep, a plateau and so on.

If you are worried about how well it seems to be working, why not start by talking to a doctor?

See pricing plans

About self-pay treatment and off-label use

Self-pay treatment
Medical weight loss is self-pay treatment (paid in full by the patient) and is not covered by public health insurance.
Off-label use
Using medicines for weight management or weight loss may be off-label use, outside the indications approved in Japan.
Relief System for Adverse Drug Reactions
With off-label use, health damage such as a serious side effect may not be covered by Japan’s Relief System for Adverse Drug Reactions.
Individual differences and the doctor’s judgment
Effects and side effects vary from person to person. A doctor decides after a consultation whether you can use a medicine and which medicine and dose are appropriate. Please tell us in advance about any symptoms, chronic conditions or medicines you are taking.

FAQ: not losing weight on Mounjaro

QI’m taking Mounjaro injections but not losing any weight at all. Does that mean the medication isn’t working?
A

Not necessarily. Your diet, protein intake, sleep, a plateau and other factors may be playing a role. Do not increase or stop the dose on your own; talk to your doctor first.

QWill I definitely lose weight if I increase the dose?
A

Increasing the dose may make it more effective, but weight loss is not guaranteed. Increasing the dose also carries a risk of side effects, so consider it based on your doctor’s judgment, not on your own.

QHow long does a plateau last?
A

It varies from person to person, but in many cases weight starts changing again after a few weeks. It is important to keep recording your meals and reviewing your lifestyle during a plateau.

QI feel the effect wears off in the second half of the week. Is that normal?
A

Because the drug’s blood concentration falls as time passes after an injection, some people feel the effect getting stronger and weaker. If strong hunger or changes in how you feel continue, talk to your doctor about the dosing interval and dose.

QHow long should I wait and see before consulting a doctor?
A

If your weight has barely changed for one to two months or more even after reviewing your lifestyle, or if you have concerns about your health, consult the prescribing doctor early.

For other questions, please also see our FAQ page.
See frequently asked questions

Not sure? Talk to us

No consultation fee (first & follow-up visits)Online consultation available

Toll-free 0120-241-929 (toll-free in Japan, 9:00–18:00 JST, Japanese only)

See prices

References and evidence

  1. Rosenstock J, et al. “Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial.” Lancet. 2021;398(10295):143-155.
  2. Frías JP, et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2).” N Engl J Med. 2021;385:503-515.
  3. Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).” N Engl J Med. 2022;387:205-216. 

Who to contact if you have side effects | When to seek care

If you have any of the following symptoms, do not wait and see on your own; contact us. GIP/GLP-1 receptor agonists, including Mounjaro, are known to cause side effects, mainly gastrointestinal symptoms. Most are mild, but serious ones occur in rare cases.

SymptomPossible causeWhat to do
Ongoing nausea or vomitingGastrointestinal symptoms; the most common side effectContact us if you remain unable to keep fluids down
Severe abdominal pain (pain that goes through to the back)Possible acute pancreatitisStop the medication immediately and seek medical care
Cold sweats, palpitations, intense hunger, or feeling confused or drowsyHypoglycemiaTake some sugar right away and contact us
Skin rash, difficulty breathing, or swelling of the face or throatAllergic reactionSeek medical care immediately
Contact: 0120-241-929 (9:00–18:00)

If your symptoms are severe outside these hours, please go to your nearest emergency medical facility.

Direct phone numbers for each clinic are listed on the clinic information page.

References

The information about medications in this article is based on the following official sources. For details on dosage, administration and side effects, always check the latest electronic package insert.
Pharmaceuticals and Medical Devices Agency (PMDA): “Mounjaro Subcutaneous Injection Ateos, electronic package insert”
PMDA: “Drug Guide for Patients: Mounjaro Subcutaneous Injection Ateos” (PDF)
Ministry of Health, Labour and Welfare: “Prevention of lifestyle-related diseases”

Using Mounjaro for purposes other than obesity disease is self-pay treatment and is not covered by public health insurance. Effects and side effects vary from person to person.

Medically reviewed by: Dr. Hiroko Oka (Chair, Medical Corporation Fukubikai / Certified Member, Japanese Society of Internal Medicine)

Reviewing doctor: Hiroko Oka
Reviewing doctor

Hiroko OkaDirector, Hiro Clinic Kawaguchi (physician)

Japanese Society of Internal Medicine About our medical review and editorial policy

You may also like

Back to all articles

Ask our AI chat AI chat